TY - JOUR
KW - *Breast Neoplasms/chemically induced/epidemiology
KW - Case-Control Studies
KW - Estrogen Replacement Therapy/adverse effects
KW - Estrogens/adverse effects
KW - Female
KW - Humans
KW - Menopause
KW - Progesterone/adverse effects
KW - Progestins/therapeutic use
KW - Risk Factors
AU - H. Abenhaim
AU - S. Suissa
AU - L. Azoulay
AU - A. Spence
AU - N. Czuzoj-Shulman
AU - T. Tulandi
AD - Department of Obstetrics & Gynecology, Jewish General Hospital, the Center for Clinical Epidemiology, Lady Davis Institute, and Epidemiology, Biostatistics, and Occupational Health, McGill University, Montréal, Québec, Canada.
AN - 35675607
BT - Obstet Gynecol
DO - 10.1097/aog.0000000000004723
DP - NLM
ET - 2022/06/09
LA - eng
M1 - 6
N1 - 1873-233x
Abenhaim, Haim A
Suissa, Samy
Azoulay, Laurent
Spence, Andrea R
Czuzoj-Shulman, Nicholas
Tulandi, Togas
Journal Article
United States
Obstet Gynecol. 2022 Jun 1;139(6):1103-1110. doi: 10.1097/AOG.0000000000004723. Epub 2022 May 3.
PY - 2022
SN - 0029-7844
SP - 1103
EP - 1110
T2 - Obstet Gynecol
TI - Menopausal Hormone Therapy Formulation and Breast Cancer Risk
VL - 139
ER -